vs
ITRON, INC.（ITRI）与Royalty Pharma plc（RPRX）财务数据对比。点击上方公司名可切换其他公司
Royalty Pharma plc的季度营收约是ITRON, INC.的1.1倍（$622.0M vs $587.0M），Royalty Pharma plc净利率更高（34.4% vs 9.1%，领先25.3%），Royalty Pharma plc同比增速更快（4.8% vs -3.3%），过去两年Royalty Pharma plc的营收复合增速更高（4.6% vs -1.8%）
Itron, Inc.是美国一家专注于能源与水资源管理的技术企业，总部位于华盛顿州自由湖。公司提供电、气、水及热能计量设备、控制技术、通信系统、配套软件，同时还提供托管运营及咨询服务，可对能源和水资源的消耗情况进行计量与深度分析，助力相关领域的资源高效管理。
本公司是总部位于美国马萨诸塞州剑桥市的临床阶段生物制药企业，专注于研发可调节转化生长因子β（TGF-β）超家族蛋白的药物，该类蛋白在红细胞、肌肉、骨骼、血管等细胞与组织的生长修复过程中发挥核心作用。
ITRI vs RPRX — 直观对比
营收规模更大
RPRX
是对方的1.1倍
$587.0M
营收增速更快
RPRX
高出8.1%
-3.3%
净利率更高
RPRX
高出25.3%
9.1%
两年增速更快
RPRX
近两年复合增速
-1.8%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $587.0M | $622.0M |
| 净利润 | $53.6M | $214.2M |
| 毛利率 | 40.3% | — |
| 营业利润率 | 11.5% | 62.4% |
| 净利率 | 9.1% | 34.4% |
| 营收同比 | -3.3% | 4.8% |
| 净利润同比 | -18.0% | 2.9% |
| 每股收益（稀释后） | $1.18 | $0.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ITRIRPRX
| Q1 26 | $587.0M | — | ||
| Q4 25 | $571.7M | $622.0M | ||
| Q3 25 | $581.6M | $609.3M | ||
| Q2 25 | $606.8M | $578.7M | ||
| Q1 25 | $607.2M | $568.2M | ||
| Q4 24 | $612.9M | $593.6M | ||
| Q3 24 | $615.5M | $564.7M | ||
| Q2 24 | $609.1M | $537.3M |
净利润ITRIRPRX
| Q1 26 | $53.6M | — | ||
| Q4 25 | $101.6M | $214.2M | ||
| Q3 25 | $65.6M | $288.2M | ||
| Q2 25 | $68.3M | $30.2M | ||
| Q1 25 | $65.5M | $238.3M | ||
| Q4 24 | $58.1M | $208.2M | ||
| Q3 24 | $78.0M | $544.0M | ||
| Q2 24 | $51.3M | $102.0M |
毛利率ITRIRPRX
| Q1 26 | 40.3% | — | ||
| Q4 25 | 40.5% | — | ||
| Q3 25 | 37.7% | — | ||
| Q2 25 | 36.9% | — | ||
| Q1 25 | 35.8% | — | ||
| Q4 24 | 34.9% | — | ||
| Q3 24 | 34.1% | — | ||
| Q2 24 | 34.6% | — |
营业利润率ITRIRPRX
| Q1 26 | 11.5% | — | ||
| Q4 25 | 13.8% | 62.4% | ||
| Q3 25 | 14.1% | 70.1% | ||
| Q2 25 | 12.6% | 36.3% | ||
| Q1 25 | 12.6% | 94.0% | ||
| Q4 24 | 10.2% | 60.9% | ||
| Q3 24 | 12.0% | — | ||
| Q2 24 | 10.6% | 50.2% |
净利率ITRIRPRX
| Q1 26 | 9.1% | — | ||
| Q4 25 | 17.8% | 34.4% | ||
| Q3 25 | 11.3% | 47.3% | ||
| Q2 25 | 11.3% | 5.2% | ||
| Q1 25 | 10.8% | 41.9% | ||
| Q4 24 | 9.5% | 35.1% | ||
| Q3 24 | 12.7% | 96.3% | ||
| Q2 24 | 8.4% | 19.0% |
每股收益（稀释后）ITRIRPRX
| Q1 26 | $1.18 | — | ||
| Q4 25 | $2.20 | $0.49 | ||
| Q3 25 | $1.41 | $0.67 | ||
| Q2 25 | $1.47 | $0.07 | ||
| Q1 25 | $1.42 | $0.55 | ||
| Q4 24 | $1.26 | $0.46 | ||
| Q3 24 | $1.70 | $1.21 | ||
| Q2 24 | $1.10 | $0.23 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $712.9M | $618.7M |
| 总债务越低越好 | — | $9.0B |
| 股东权益账面价值 | $1.6B | $9.7B |
| 总资产 | $4.0B | $19.6B |
| 负债/权益比越低杠杆越低 | — | 0.92× |
8季度趋势，按日历期对齐
现金及短期投资ITRIRPRX
| Q1 26 | $712.9M | — | ||
| Q4 25 | $1.0B | $618.7M | ||
| Q3 25 | $1.3B | $938.9M | ||
| Q2 25 | $1.2B | $631.9M | ||
| Q1 25 | $1.1B | $1.1B | ||
| Q4 24 | $1.1B | $929.0M | ||
| Q3 24 | $982.5M | $950.1M | ||
| Q2 24 | $920.6M | $1.8B |
总债务ITRIRPRX
| Q1 26 | — | — | ||
| Q4 25 | $1.3B | $9.0B | ||
| Q3 25 | — | $8.9B | ||
| Q2 25 | — | $8.0B | ||
| Q1 25 | — | $7.6B | ||
| Q4 24 | $1.3B | $7.6B | ||
| Q3 24 | $1.3B | $7.6B | ||
| Q2 24 | $1.3B | $7.6B |
股东权益ITRIRPRX
| Q1 26 | $1.6B | — | ||
| Q4 25 | $1.7B | $9.7B | ||
| Q3 25 | $1.7B | $9.6B | ||
| Q2 25 | $1.6B | $9.5B | ||
| Q1 25 | $1.5B | $9.8B | ||
| Q4 24 | $1.4B | $10.3B | ||
| Q3 24 | $1.3B | $10.3B | ||
| Q2 24 | $1.2B | $9.8B |
总资产ITRIRPRX
| Q1 26 | $4.0B | — | ||
| Q4 25 | $3.7B | $19.6B | ||
| Q3 25 | $3.7B | $19.3B | ||
| Q2 25 | $3.6B | $18.3B | ||
| Q1 25 | $3.5B | $17.6B | ||
| Q4 24 | $3.4B | $18.2B | ||
| Q3 24 | $3.4B | $18.0B | ||
| Q2 24 | $3.3B | $17.7B |
负债/权益比ITRIRPRX
| Q1 26 | — | — | ||
| Q4 25 | 0.74× | 0.92× | ||
| Q3 25 | — | 0.93× | ||
| Q2 25 | — | 0.84× | ||
| Q1 25 | — | 0.78× | ||
| Q4 24 | 0.91× | 0.74× | ||
| Q3 24 | 0.94× | 0.74× | ||
| Q2 24 | 1.02× | 0.78× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $85.5M | $827.1M |
| 自由现金流经营现金流 - 资本支出 | $79.0M | — |
| 自由现金流率自由现金流/营收 | 13.5% | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | 1.60× | 3.86× |
| 过去12个月自由现金流最近4个季度 | $394.6M | — |
8季度趋势，按日历期对齐
经营现金流ITRIRPRX
| Q1 26 | $85.5M | — | ||
| Q4 25 | $119.3M | $827.1M | ||
| Q3 25 | $117.8M | $702.6M | ||
| Q2 25 | $96.7M | $364.0M | ||
| Q1 25 | $72.1M | $596.1M | ||
| Q4 24 | $79.8M | $742.5M | ||
| Q3 24 | $65.3M | $703.6M | ||
| Q2 24 | $51.7M | $658.2M |
自由现金流ITRIRPRX
| Q1 26 | $79.0M | — | ||
| Q4 25 | $111.5M | — | ||
| Q3 25 | $113.4M | — | ||
| Q2 25 | $90.7M | — | ||
| Q1 25 | $67.5M | — | ||
| Q4 24 | $70.2M | — | ||
| Q3 24 | $58.7M | — | ||
| Q2 24 | $44.6M | — |
自由现金流率ITRIRPRX
| Q1 26 | 13.5% | — | ||
| Q4 25 | 19.5% | — | ||
| Q3 25 | 19.5% | — | ||
| Q2 25 | 14.9% | — | ||
| Q1 25 | 11.1% | — | ||
| Q4 24 | 11.4% | — | ||
| Q3 24 | 9.5% | — | ||
| Q2 24 | 7.3% | — |
资本支出强度ITRIRPRX
| Q1 26 | — | — | ||
| Q4 25 | 1.4% | — | ||
| Q3 25 | 0.8% | — | ||
| Q2 25 | 1.0% | — | ||
| Q1 25 | 0.8% | — | ||
| Q4 24 | 1.6% | — | ||
| Q3 24 | 1.1% | — | ||
| Q2 24 | 1.2% | — |
现金转化率ITRIRPRX
| Q1 26 | 1.60× | — | ||
| Q4 25 | 1.17× | 3.86× | ||
| Q3 25 | 1.80× | 2.44× | ||
| Q2 25 | 1.41× | 12.06× | ||
| Q1 25 | 1.10× | 2.50× | ||
| Q4 24 | 1.37× | 3.57× | ||
| Q3 24 | 0.84× | 1.29× | ||
| Q2 24 | 1.01× | 6.45× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ITRI
| Product revenues | $477.8M | 81% |
| Service revenues | $109.2M | 19% |
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
